Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Vaccines against drug abuse.

Literature DB >> 22130115

Vaccines against drug abuse.

Abstract

The currently available medications for the treatment of drug abuse have had only limited success. Anti-addiction vaccines, aimed at eliciting antibodies that block the pharmacological effects of drugs, have great potential for treating drug abuse. We review the status of two vaccines that are undergoing clinical trials (for cocaine and nicotine addiction) and two that are still in preclinical development (for methamphetamine and heroin addiction). We also outline the challenges and ethical concerns associated with the development of anti-addiction vaccines and their use as future therapeutics.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Vaccines

Year: 2011 PMID： 22130115 PMCID： PMC3345810 DOI： 10.1038/clpt.2011.281

Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875

72 in total

Review 1. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.

Authors: Tino F Schwarz
Journal: Adv Ther Date: 2009-12-18 Impact factor: 3.845

Review 2. New adjuvants for human vaccines.

Authors: M Lamine Mbow; Ennio De Gregorio; Nicholas M Valiante; Rino Rappuoli
Journal: Curr Opin Immunol Date: 2010-05-11 Impact factor: 7.486

Review 3. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence.

Authors: J Taylor Hays; Jon O Ebbert
Journal: Drugs Date: 2010-12-24 Impact factor: 9.546

4. Pharmacotherapy in the treatment of addiction: methadone.

Authors: Mary Jeanne Kreek; Lisa Borg; Elizabeth Ducat; Brenda Ray
Journal: J Addict Dis Date: 2010-04

Review 5. Oral naltrexone maintenance treatment for opioid dependence.

Authors: Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal: Cochrane Database Syst Rev Date: 2011-02-16

6. Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications.

Authors: Nora D Volkow; Joanna S Fowler; Gene-Jack Wang; Elena Shumay; Frank Telang; Peter K Thanos; David Alexoff
Journal: PLoS One Date: 2010-12-07 Impact factor: 3.240

7. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans.

Authors: Margaret Haney; Erik W Gunderson; Huiping Jiang; Eric D Collins; Richard W Foltin
Journal: Biol Psychiatry Date: 2010-01-01 Impact factor: 13.382

Review 8. Vaccine adjuvants: putting innate immunity to work.

Authors: Robert L Coffman; Alan Sher; Robert A Seder
Journal: Immunity Date: 2010-10-29 Impact factor: 31.745

Review 9. The methamphetamine problem in the United States.

Authors: Rachel Gonzales; Larissa Mooney; Richard A Rawson
Journal: Annu Rev Public Health Date: 2010 Impact factor: 21.981

10. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.

Authors: D K Hatsukami; D E Jorenby; D Gonzales; N A Rigotti; E D Glover; C A Oncken; D P Tashkin; V I Reus; R C Akhavain; R E F Fahim; P D Kessler; M Niknian; M W Kalnik; S I Rennard
Journal: Clin Pharmacol Ther Date: 2011-01-26 Impact factor: 6.875

51 in total

1. Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers.

Authors: R De La Garza; T F Newton; C N Haile; J H Yoon; C S Nerumalla; J J Mahoney; A Aziziyeh
Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2011-12-30 Impact factor: 5.067

2. Investigations into the efficacy of multi-component cocaine vaccines.

Authors: Atsushi Kimishima; Margaret E Olson; Kim D Janda
Journal: Bioorg Med Chem Lett Date: 2017-12-20 Impact factor: 2.823

3. An enzymatic advance in nicotine cessation therapy.

Authors: Song Xue; Marsida Kallupi; Bin Zhou; Lauren C Smith; Pedro O Miranda; Olivier George; Kim D Janda
Journal: Chem Commun (Camb) Date: 2018-02-13 Impact factor: 6.222

4. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

Authors: Rashmi Jalah; Oscar B Torres; Alexander V Mayorov; Fuying Li; Joshua F G Antoline; Arthur E Jacobson; Kenner C Rice; Jeffrey R Deschamps; Zoltan Beck; Carl R Alving; Gary R Matyas
Journal: Bioconjug Chem Date: 2015-06-05 Impact factor: 4.774

5. The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse.

Authors: Megan Laudenbach; Federico Baruffaldi; Jeffrey S Vervacke; Mark D Distefano; Philip J Titcombe; Daniel L Mueller; Noah J Tubo; Thomas S Griffith; Marco Pravetoni
Journal: J Immunol Date: 2015-05-13 Impact factor: 5.422